Discordant Endorsement of Prostate Cancer Biomarkers Across Major Guidelines.

{"article_title":"Discordant Endorsement of Prostate Cancer Biomarkers Across Major Guidelines.","author":"Pratsinis M, Dall'Era M","journal_title":"European urology focus","issn":"2405-4569","isbn":"","publication_date":"2022-07-01","volume":"8","issue":"4","first_page":"919","page_count":"","accession_number":"36031558","doi":"10.1016\/j.euf.2022.08.008","publisher":"Elsevier B.V","doctype":"Practice Guideline","subjects":"Prostate-Specific Antigen; Prostatic Neoplasms diagnosis; Biomarkers, Tumor; Humans; Male; Pelvis; Prostate","interest_area":["Oncology"," Obstetrics & Gynecology"],"abstract":"Prostate cancer is the most common solid cancer among men. Multiple blood-, urine-, and tissue-based biomarkers are currently commercially available and can improve the detection and risk stratification of prostate cancer. These biomarkers are still novel, however, and long-term data on their efficacy are still lacking. We compared recommendations on the use of biomarkers across major guidelines for different clinical scenarios. There is no consensus among the international guidelines regarding the optimal use of biomarkers for prostate cancer. As biomarker use in prostate cancer is still in its infancy, it remains to be seen whether there will be alignment of the guidelines with an increasing body of evidence generated . PATIENT SUMMARY: Various biomarkers beyond prostate-specific antigen (PSA) have recently been developed to improve detection and risk stratification of prostate cancer. We compared recommendations on the use of these biomarkers across major guidelines. There is currently little agreement between these guidelines on the optimal use of biomarkers in prostate cancer. Copyright \u00a9 2022 The Author(s). Published by Elsevier B.V. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=36031558","isPdfLink":false,"isSAML":false,"an":"36031558","number_other":"","type_pub":"","issn_electronic":"2405-4569","languages":"English","language":"eng","date_entry":"Date Created: 20220828 Date Completed: 20221010 Latest Revision: 20231129","date_update":"20240104","titleSource":"European urology focus [Eur Urol Focus] 2022 Jul; Vol. 8 (4), pp. 919-921. Date of Electronic Publication: 2022 Aug 26.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-07-01","description":"Prostate cancer is the most common solid cancer among men. Multiple blood-, urine-, and tissue-based biomarkers are currently commercially available and can improve the detection and risk stratification of prostate cancer. These biomarkers are still novel, however, and long-term data on their efficacy are still lacking. We compared recommendations on the use of biomarkers across major guidelines for different clinical scenarios. There is no consensus among the international guidelines regarding the optimal use of biomarkers for prostate cancer. As biomarker use in prostate cancer is still in its infancy, it remains to be seen whether there will be alignment of the guidelines with an increasing body of evidence generated . PATIENT SUMMARY: Various biomarkers beyond prostate-specific antigen (PSA) have recently been developed to improve detection and risk stratification of prostate cancer. We compared recommendations on the use of these biomarkers across major guidelines. There is currently little agreement between these guidelines on the optimal use of biomarkers in prostate cancer.<br \/> (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=36031558&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Pratsinis M, Dall'Era M"}